Australia markets closed

Context Therapeutics Inc. (CNTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.9601+0.0481 (+5.27%)
At close: 03:59PM EST
0.9900 +0.03 (+3.11%)
Pre-market: 07:26AM EST

Context Therapeutics Inc.

2001 Market Street
Suite 3915 Unit #15
Philadelphia, PA 19103
United States
267 225 7416

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Martin A. LehrCo-Founder, Pres, CEO & Director523.71kN/A1984
Ms. Jennifer Minai-AzaryCFO & Treasurer404.33kN/A1978
Mr. Alex C. Levit Esq.Chief Legal Officer & Corp. Sec.490.82kN/A1979
Dr. Felix Kim Ph.D.Co-founder & Chair of Scientific Advisory BoardN/AN/AN/A
Mr. Christopher Beck M.B.A.Sr. VP of OperationsN/AN/AN/A
Dr. Tarek Sahmoud M.D., Ph.D.Chief Medical OfficerN/AN/A1961
Dr. Evan G. DickSr. VP of R&DN/AN/A1952
Ms. Elizabeth Nemchik CPAControllerN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Corporate governance

Context Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.